Impax signs multiproduct agreement with Tolmar
Impax Laboratories president and CEO Larry Hsu said in the past two years, the company has entered into four distinct partnerships for alternative dosage form products. "Our business
Kyowa Kirin subsidiary Kyowa Kirin EMEA has received approval from the European Commission (EC) to expand the use of Crysvita (burosumab) for treating X-linked hypophosphataemia (XLH) in infants aged one month to one year across the EU and European Economic Area.